Metal-based anticancer agents as immunogenic cell death inducers: the past, present, and future

210 indexed citations

Abstract

loading...

About

This paper, published in 2022, received 210 indexed citations. Written by Sajal Sen, Miae Won, Matthew S. Levine, Adam C. Sedgwick, Jong Seung Kim, Jonathan L. Sessler and Jonathan F. Arambula covering the research area of Oncology and Immunology. It is primarily cited by scholars working on Biomedical Engineering (95 citations), Oncology (70 citations) and Organic Chemistry (51 citations). Published in Chemical Society Reviews.

Countries where authors are citing Metal-based anticancer agents as immunogenic cell death inducers: the past, present, and future

Specialization
Citations

This map shows the geographic impact of Metal-based anticancer agents as immunogenic cell death inducers: the past, present, and future. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Metal-based anticancer agents as immunogenic cell death inducers: the past, present, and future with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Metal-based anticancer agents as immunogenic cell death inducers: the past, present, and future more than expected).

Fields of papers citing Metal-based anticancer agents as immunogenic cell death inducers: the past, present, and future

Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of Metal-based anticancer agents as immunogenic cell death inducers: the past, present, and future. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the Metal-based anticancer agents as immunogenic cell death inducers: the past, present, and future.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

This paper is also available at doi.org/10.1039/d1cs00417d.

Explore hit-papers with similar magnitude of impact

Breakdown of academic impact, for the paper Forcing Factors Affecting Sea Level Changes at the Coast Breakdown of academic impact, for the paper Privacy preservation in federated learning: An insightful survey from the GDPR perspective Breakdown of academic impact, for the paper Two electrolyte decomposition pathways at nickel-rich cathode surfaces in lithium-ion batteries Breakdown of academic impact, for the paper Electrochemical C–N coupling of CO2and nitrogenous small molecules for the electrosynthesis of organonitrogen compounds Breakdown of academic impact, for the paper Revisiting the Physicochemical Properties and Applications of Deep Eutectic Solvents Breakdown of academic impact, for the paper Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial Breakdown of academic impact, for the paper IoT-Equipped and AI-Enabled Next Generation Smart Agriculture: A Critical Review, Current Challenges and Future Trends Breakdown of academic impact, for the paper Parents’ Intentions and Perceptions About COVID-19 Vaccination for Their Children: Results From a National Survey Breakdown of academic impact, for the paper Staphylococcus aureus Toxins: An Update on Their Pathogenic Properties and Potential Treatments Breakdown of academic impact, for the paper Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance
Rankless by CCL
2026